Matthew B. Klein - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: PTCT
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2026, 17:20:06 UTC
Prior SEC filing: 02 Jan 2026
Next SEC filing: 08 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Avraham S. Adler, Attorney-in-Fact

Key filing fact

Matthew B. Klein filed Form 4 for PTC THERAPEUTICS, INC. (PTCT) on 06 Jan 2026.

Key facts

This page summarizes Matthew B. Klein's Form 4 filing for PTC THERAPEUTICS, INC. (PTCT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2026, 17:20.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808968 Primary reporting owner

Klein Matthew B.

Relationship: CHIEF EXECUTIVE OFFICER, Director
Address: C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN
Signature: /s/ Avraham S. Adler, Attorney-in-Fact
Signature date: 06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTCT transaction

Common Stock

Award

Transaction value: $0
Shares: +63,000
Change %: +18%
Price: $0.000000
Shares after: 405,132
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTCT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +157,500
Change %
Price: $0.000000
Shares after: 157,500
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 157,500
Exercise price: $76.74
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.

Footnote F2

Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.

Footnote F3

This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.